Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CLSD - Clearside Biomedical, Inc.
Market Cap 70.30M P/E - EPS this Y 5.70% Ern Qtrly Grth -
Income -33.46M Forward P/E -1.93 EPS next Y -4.00% 50D Avg Chg -5.00%
Sales 7.52M PEG - EPS past 5Y - 200D Avg Chg -5.00%
Dividend N/A Price/Book 25.91 EPS next 5Y - 52W High Chg -38.00%
Recommedations 1.70 Quick Ratio 5.00 Shares Outstanding 74.75M 52W Low Chg 27.00%
Insider Own 7.39% ROA -44.05% Shares Float 69.16M Beta 2.35
Inst Own 26.33% ROE - Shares Shorted/Prior 273.44K/180.15K Price 1.14
Gross Margin 98.11% Profit Margin - Avg. Volume 125,620 Target Price 5.57
Oper. Margin -8,433.33% Earnings Date Nov 11 Volume 42,613 Change -0.87%
Healthcare | Biotechnology | United States
About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Clearside Biomedical, Inc. News
12/20/24 Clearside announces publication of insights on drug development, regulation
12/20/24 Analyst Sees 500% Upside for This Pharmaceutical Penny Stock
12/19/24 Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
12/12/24 Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now
11/25/24 Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
11/15/24 All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy
11/15/24 Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations
11/13/24 Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ...
11/12/24 Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates
11/12/24 Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
11/10/24 Even after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three years
11/08/24 Santen, Arctic Vision sign deal for ARVN001 to treat UME
11/07/24 Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
11/06/24 Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
11/04/24 Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
10/31/24 Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
10/22/24 Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
10/10/24 Morning Movers: Arcadium Lithium surges after deal to be acquired
10/09/24 Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study
10/09/24 Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
LASEZKAY GEORGE M CEO CEO Jan 18 Sell 1.27 18,000 22,860 466,577 01/19/24
Deignan Charles A. Chief Financial Offi.. Chief Financial Officer Jan 18 Sell 1.28 12,900 16,512 384,662 01/19/24
Hutson Nancy J Director Director Oct 03 Buy 0.86 10,000 8,600 93,000 10/04/23
Thorp Clay Director Director Sep 25 Buy 0.86 10,000 8,600 40,522 09/25/23
Humphries William D. Director Director Sep 22 Option 0.40 22,727 9,091 51,040 09/22/23
Deignan Charles A. Chief Financial Offi.. Chief Financial Officer Sep 13 Option 0.40 34,090 13,636 397,562 09/13/23
Ciulla Thomas Chief Medical Office.. Chief Medical Officer Jan 10 Sell 1.62 2,170 3,515 305,590 01/11/23
Thorp Clay Director Director Feb 10 Sell 4.43 32,873 145,627 4,951,547 12/19/22
Hutson Nancy J Director Director Nov 17 Buy 1.33 30,000 39,900 83,000 11/21/22
Deignan Charles A. Chief Financial Offi.. Chief Financial Officer Jan 18 Sell 2.09 8,833 18,461 351,366 01/20/22
Ciulla Thomas Chief Medical Office.. Chief Medical Officer Jan 18 Sell 2.13 9,050 19,276 295,260 01/20/22
LASEZKAY GEORGE M CEO CEO Jan 18 Sell 2.12 10,800 22,896 504,607 01/20/22
Humphries William D. Director Director Jan 10 Option 0.15 22,727 3,409 28,313 01/11/22
WHITMORE BRADFORD T 10% Owner 10% Owner Sep 01 Sell 6.97 420,285 2,929,386 2,415,056 09/01/21